Importance: Endoglin (CD105) and endothelial nitric oxide synthase (eNOS) assist in regulating vascular development. Variation in expression of these factors is linked to errors in vascular growth and remodeling in invasive lesions.
A
RTERIOVENOUS MALFORMAtions (AVMs) represent a rare form of high-flow vascular anomaly (VA) that most commonly occurs in the head and neck. 1, 2 They are present at birth but are usually clinically asymptomatic until later in life. The pathogenesis of AVMs remains unclear. They are known to arise from multiple aberrant arteriovenous shunts between arteries and veins and consist of numerous hypertrophic, poorly regulated, and tortuous arteries and veins. Unlike infantile hemangiomas (IHs), another form of high-flow VA that results from endothelial cell (EC) proliferation and excess angiogenesis, the development of AVMs is more likely associated with hemodynamic imbalance, vascular remodeling, and embryologic precursors. [1] [2] [3] Arteriovenous malformations tend to progress slowly, but prior therapy, pregnancy, or trauma may cause their rapid enlargement. [3] [4] [5] [6] [7] With time, AVMs will expand to excessive size and infiltrate local tissue. This relentless growth causes a mass effect on surrounding tissues, with functional deficits, aesthetic impairment, and life-threatening bleeding. Ultimately, most AVMs will need to be treated. Unfortunately, no current therapeutic modality is ideal for the control of AVMs. Exacerbating this issue is that AVMs are difficult to positively identify from other VAs by light microscopy and histopathology alone. Specific markers are unavailable to reliably diagnose AVMs. This diagnostic challenge is reflected and compounded by a poor understanding of the pathogenesis of AVMs, leading to invalid treatment protocols.
Angiogenesis and vascular development are closely regulated by molecular pathways generated by the transforming growth factor ␤ receptor endoglin (CD105) and the nitric oxide (NO)-producing enzyme endothelial NO synthase (eNOS) in normal tissues and in tumors. Most importantly, their pathways intersect in the process of vascular remodeling and growth. 12, 13 Arteriovenous malformations are presumed to have an inherent disruption of this process, with CD105 recently discovered to be mutated in some forms of small AVMs 14 and implicated in pathological development of brain AVMs. 15 Similarly, eNOS has been found to be abnormally expressed in other forms of high-flow VAs. 1 Therefore, we hypothesized that CD105 and eNOS are involved in the growth and recurrence of extracranial AVMs. This study focused on the pathogenesis of AVMs through examination of CD105 and eNOS, factors known to be involved in hemodynamic control and vascular remodeling. Direct comparison of expression in IHs and in normal skin with subcutaneous tissue is made to help us better understand the role of these 2 factors.
METHODS

SPECIMENS
This study was approved by the institutional review board of the University of Arkansas for Medical Sciences. After obtaining informed consent, fresh surgical specimens of head and neck subcutaneous AVM tissues were obtained from 14 patients. Infantile hemangiomas and normal skin with subcutaneous tissue were obtained from 9 patients each.
Histologic examination by a pathologist (C.-Y.F. or A.G.S.) experienced with VAs confirmed the diagnosis for each patient at the time of resection. GLUT-1 staining helped confirm the IH diagnosis (when positive) or the AVM diagnosis (when negative) in these high-flow vascular lesions. Specimens were then divided for storing at -80ЊC and formalin fixation (10%) with paraffin embedding.
IMMUNOHISTOCHEMISTRY
After deparaffinization and rehydration, the sections were heated to 97ЊC for 20 minutes in a water bath in the presence of antigen retrieval solution (CITRA, pH 6.0; Invitrogen) and cooled for 30 minutes. To block the endogenous peroxidase activity, all sections were incubated with hydrogen peroxide for 10 minutes and washed with a phosphate-buffered saline solution (pH 7.4; Sigma-Aldrich). The sections were preincubated with 2% nonfat milk for 30 minutes at room temperature. Then, the sections were incubated in primary eNOS (rabbit polyclonal antibody; Santa Cruz Biotechnology) at 1:500 dilution or CD105 (mouse monoclonal antibody; Thermo Fisher Scientific) at 1:150 dilution for 20 hours at 4ЊC. After washing with a phosphatebuffered saline solution, the sections were incubated in primary antibody enhancer (Thermo Fisher Scientific) for 10 minutes and horseradish peroxidase polymer (Thermo Fisher Scientific) for 15 minutes at room temperature. After washing the sections in a phosphate-buffered saline solution, they were incubated with diaminobenzidine (Thermo Fisher Scientific) for 3 minutes at room temperature. The sections were counterstained with hematoxylin for 30 seconds. Next, they were dehydrated through graded alcohol solutions and cleaned by xylene substitute. Then, they were mounted (with Permount; Thermo Fisher Scientific) and coverslipped.
Human tonsil tissue was used as a positive control for CD105 antibody. Mouse brain tissue was used as a positive control for eNOS antibody. Slides with no primary antibody applied were used as the negative control. The staining results were validated by a blind review performed by a pathologist (C.-Y.F. or A.G.S.) with extensive experience examining VAs and immunohistochemistry. A strong staining in greater than 10% of the cells indicated a positive value.
WESTERN BLOT
Total proteins were extracted from 10-mg sections of frozen specimen with 200 L of tissue protein extraction reagent (Pierce) added with protease inhibitor (Mini Protease Inhibitor Cocktail; Roche). Thirty micrograms of the total protein was loaded on gels (NuPAGE 4%-12% Bis-Tri; Invitrogen) for electrophoresis, transferred to a nitrocellulose membrane, and probed with rabbit polyclonal antibody against eNOS (Santa Cruz Biotechnology) at 1:200 dilution, mouse monoclonal antibody against CD105 (Thermo Fisher Scientific) at 1:150 dilution, or mouse monoclonal antibody against ␤-actin (Santa Cruz Biotechnology) at 1:1000 dilution. The blot was incubated with a horseradish peroxidase-conjugated goat antirabbit IgG (Invitrogen) or goat antimouse IgG (Invitrogen), and the protein was visualized using a kit (Novex ECL Chemiluminescent Substrate Reagent Kit; Invitrogen). CD105 and eNOS protein expression levels were semiquantitatively assessed in comparison with ␤-actin level using available software (Image J; National Institutes of Health).
STATISTICAL ANALYSIS
Western blot results were expressed as means (SDs). The differences between any 2 groups were calculated using the t test. PϽ.05 was considered statistically significant.
RESULTS
IMMUNOHISTOCHEMISTRY
All AVM specimens (n=14) were positive for CD105 and eNOS expression by immunohistochemistry. Both CD105 and eNOS were located primarily in AVM ECs. All IH specimens (n=9) were positive for eNOS but were negative for CD105. As in the case of AVMs, eNOS was located in the IH ECs. All samples of normal skin with subcutaneous tissue (n = 9) were negative for eNOS and CD105. Results from this staining are shown in Figure 1 and cardiovascular development. 12, 18, 19 It is expressed on activated vascular ECs 20 and will mediate EC proliferation, migration, and tube formation when binding with transforming growth factor ␤. 21 Although the exact mechanism of CD105 is unknown, there is no doubt that CD105 is a marker of proliferating ECs. 22 CD105 is highly expressed in numerous solid tumors and is known to be involved in tumor angiogenesis and metastasis. CD105 is found on ECs and in mesenchymal stem cells, which are abundant in tumors. Many clinical studies have reported that CD105 is a useful tumor vasculature marker because it is more specific than traditional markers, such as CD31, CD34, and factor VIII. This is because inside the tumor CD105 is expressed predominantly in angiogenic ECs undergoing vascular remodeling but not in the stable ECs of normal vasculature. Although AVMs are a type of VA, they have aggressive characteristics similar to those of locally invasive cancers. Qualities possessed by AVMs include the ability to undergo rapid expansion, achieve excessive size, infiltrate local tissue, and recur following extensive and ablative therapy.
3-7 CD105 expression has been found to be abnormal in cerebral AVMs. 15 Because of the constant remodeling presumed to occur in AVMs, the invasive quality of AVMs, and the presence of CD105 in intracranial disease, we hypothesized that CD105 was involved in the growth and recurrence of extracranial AVMs. In this study, we demonstrated that CD105 protein is predominantly located in AVM vascular ECs and that expression was significantly greater in AVM specimens than in IHs or normal skin with subcutaneous tissue. In IHs, another type of high-flow VA undergoing rapid vascular changes, CD105 protein could not be detected by immunohistochemistry or Western blot. This finding suggests that angiogenesis and vascular remodeling occur in AVMs and is consistent with recent clinical and experimental evidence. [29] [30] [31] [32] [33] [34] Our study results also posit a role of CD105 in the invasive quality of extracranial AVMs. CD105 not only promotes angiogenesis by activating endothelial proliferation pathways but also affects NO production in ECs. 35 Modulation of CD105 expression has been shown to influence NO-dependent vasodilation along with eNOS expression and activity in in vitro and in vivo models. 14, 35 These findings suggest that CD105 is an important coupler of eNOS activity and that eNOS has a major role in CD105-dependent angiogenesis.
Nitric oxide synthase comprises a family of enzymes that is responsible for production of NO from L-arginine. Three major isoforms of NOS have been found, including neuronal NOS, inducible NOS, and endothelial NOS (eNOS). 36 Endothelial NOS is constitutively expressed in the ECs, hav- ing a key role in angiogenesis and vasculogenesis. Production of NO by eNOS regulates blood vessel tone and hemodynamics, inhibits vascular smooth-muscle cell proliferation, and modulates the interaction of endothelium with leukocytes. 37 Ying and Hofseth 38 demonstrated that the eNOS and NO pathways closely modulate events in tumors, including the promotion of angiogenesis and antiapoptosis in tumor epithelial cells, stimulating cancer cell cycle progression and proliferation, and enhancing tumor cell vascular invasion.
In this study, we demonstrated that eNOS protein is predominantly located in AVM vascular ECs. Its expression was greater in AVMs than in normal skin with subcutaneous tissue. Along with our CD105 results, this finding suggests that the angiogenesis and proliferation of AVM ECs may occur due to higher-than-normal levels of CD105 and eNOS expression. In this research, a notable phenomenon was observed: AVM ECs have high expression of CD105 and eNOS, while IH ECs have only high expression of eNOS. The deficiency of CD105 in IHs is unclear.
A previous study 39 demonstrated that eNOS protein level is decreased in involuting IHs. CD105 is perhaps necessary to maintain the integrity of neovasculature in IHs. Its absence may contribute to the involuting process. Most importantly, CD105 coupling in AVMs may lead to vascular stabilization that is not present in IHs, whereas eNOS level elicits no change in AVMs (which will not spontaneously involute).
Based on work by Toporsian et al, 14 the stability of eNOS is significantly reduced in CD105-deficient ECs. Our research suggests that the gradual reduction of eNOS protein level in IHs is due to a limitation in CD105 expression.
In this research, CD105 was not expressed in the ECs of normal skin with subcutaneous tissue and IHs but was expressed in the angiogenic ECs of AVMs. This suggests that CD105 may mediate EC proliferation and migration in AVMs but not in IHs. Also, expression of CD105 in AVM ECs may have some pathological diagnostic value, providing a tool to identify small-vessel AVMs vs IHs or other high-flow vascular lesions. This is important because of the distinct nature of AVMs. Early and accurate diagnosis of these lesions will provide insight into treatment planning, which is fundamentally different from that of any hemangioma or other vascular malformations.
Recent data suggest that CD105 expression levels have prognostic value in various solid cancers. [40] [41] [42] [43] [44] [45] CD105 expression, as determined by immunohistochemical staining, has been consistently associated with lower patient survival rates.
2 While AVMs have some aggressive characteristics similar to those of locally invasive cancers, CD105 level may be a useful indicator of AVM progression and may help identify patients at risk of recurrence. Its function as a biomarker for targeted imaging and therapy remains a possibility.
In conclusion, CD105 is uniquely present at significantly increased levels in head and neck AVMs relative to IHs (another type of high-flow VA) and normal skin with subcutaneous tissue. Endothelial NOS, an enzyme involved in the constitutive expression of NO, is expressed at higher levels in the ECs of AVMs and IHs compared with normal skin. These results suggest that CD105 and eNOS expression may have an important role in vascular remodeling of AVMs and mark a collaborative and aberrant signaling pathway in the pathogenesis of extracranial AVMs. CD105 may also represent a histopathological marker for AVMs vs other VAs. Further investigation of CD105 in other malformations will help elucidate this possibility.
